Back to Browse Journals » Medicolegal and Bioethics » Volume 2

REACH, animal testing, and the precautionary principle

Authors Menache A, Nastrucci C

Published Date August 2012 Volume 2012:2 Pages 13—29

DOI http://dx.doi.org/10.2147/MB.S33044

Received 19 April 2012, Accepted 11 May 2012, Published 6 August 2012

Video abstract presented by Andre Menache

Views: 450

Andre Menache,1 Candida Nastrucci2

1Antidote Europe, Perpignan, France; 2University of Rome, "Tor Vergata", Rome, Italy

Abstract: Relatively little is known about the toxicity of the many chemicals in existence today. This has prompted European Union regulatory authorities to launch a major chemicals testing program, known as Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH). Although the driving force behind REACH is ostensibly based on the precautionary principle, in practice, the evidence suggests that it is oriented more toward risk assessment than precaution. In addition, the test methods used to assess chemical risk also raise questions about the efficacy of REACH in achieving its stated aims of protecting human health and the environment. These tests rely in large part on animal models. However, based on empirical evidence and on well-established principles of evolutionary biology and complex systems, the animal model fails as a predictive modality for humans. In turn, these concerns raise significant ethical and legal issues that must be addressed urgently. Immediate measures should include a major biomonitoring program to reliably assess the chemical burden in European Union citizens as a means of prioritizing the most dangerous substances present in the environment. Blood and urine biomarkers are useful tools with which to implement biomonitoring and to help guide public policy. An ecological paradigm, based on pollution prevention, rather than pollution control and risk assessment of individual chemicals, represents a superior strategy, to prevent global chemical pollution and toxicity risks to human health.

Keywords: precautionary principle, risk, chemicals, animal tests, biomonitoring

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

OxyContin, prescription opioid abuse and economic medicalization

Poitras G

Medicolegal and Bioethics 2012, 2:31-43

Published Date: 23 November 2012

Subsidizing artemisinin-based combination therapies: a preliminary investigation of the Affordable Medicines Facility – malaria

Bate R, Hess K, Tren R, Mooney L, Cudjoe F, Ayodele T, Attaran A

Research and Reports in Tropical Medicine 2012, 3:63-68

Published Date: 18 July 2012

An analysis of the Bateson Review of research using nonhuman primates

Greek R, Hansen LA, Menache A

Medicolegal and Bioethics 2011, 1:3-22

Published Date: 6 December 2011

Tangential vitreous traction: a possible mechanism of development of cystoid macular edema in retinitis pigmentosa

Mikiko Takezawa, Soichi Tetsuka, Akihiro Kakehashi

Clinical Ophthalmology 2011, 5:245-248

Published Date: 21 February 2011

Antimalarial medicine diversion: stock-outs and other public health problems

Roger Bate, Kimberly Hess, Lorraine Mooney

Research and Reports in Tropical Medicine 2010, 1:19-24

Published Date: 2 September 2010